Stock Analiz

Embecta Corp. EMBC

Medical/Dental Instruments · data as of November 13, 2026

$6.46Market cap $366M
Open the interactive analysis →

Embecta Corp. (EMBC) is a healthcare company listed in the US with a market value of about $366M. In the twelve months to June 30, 2026 it had revenue of $1.0B and net income of $88M, a net margin of 8.6%.

Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is value (4/5); the weakest is future growth (1/5).

Key numbers: a P/E of 4.4, a price to free cash flow of 2.2, 5-year revenue growth of -0% a year, a 5-year average ROIC of 32%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 468% above the current price.

About Embecta

Embecta is listed in the US and classified in medical/dental instruments. Revenue went from $1.1B in 2020 to $1.1B in 2025, a decline of about 0.1% a year. It was profitable in 6 of the last 6 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 3% of revenue on research and development.

Score: 2.6 / 5

Value4/5
Future growth1/5
Track record2/5
Financial health2/5
Shareholder returns4/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • Profit margin improving
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • Positive free cash flow

Checks not passed

  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year
  • ROE above 15%

Valuation

P/E (TTM)4.4
Forward P/E3.9
P/FCF2.2
P/S0.4
P/B—
EV/EBITDA5.8
PEG—
Dividend yield0.62%
FCF yield45.0%
Shareholder yield0.6%
Intrinsic value vs. price+468%

Growth and quality

Revenue growth (1 yr)-3.8%
Revenue growth (5 yrs, per year)-0.1%
EPS growth (5 yrs, per year)-26.4%
FCF growth (3 yrs, per year)-22.3%
Net margin (5-yr avg.)15.5%
ROIC (5-yr avg.)31.9%
Profitable years (of last 10)6
Years paying a dividend4

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$1.0B$1.1B$1.1B$1.1B$1.1B$1.2B$1.1B
Net income$88M$95M$78M$70M$224M$415M$428M
Free cash flow$165M$182M$20M$41M$389M$420M$457M
EPS (diluted)$1.47$1.62$1.34$1.22$3.89$7.28$7.50
Net margin8.6%8.8%7.0%6.3%19.8%35.6%39.4%
ROIC—22.2%15.4%17.7%35.5%68.9%74.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $4.00, 38% below the current price; targets range from $3.00 to $5.00; the consensus rating is “none”; expected EPS is $1.83 for the fiscal year ending September 30, 2026.

Frequently asked questions

What is Embecta’s P/E ratio?

About 4.4, based on the last twelve months of diluted earnings per share (forward P/E about 3.9).

Is Embecta stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 468% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Embecta pay a dividend?

Yes. The dividend yield is about 0.62%, and it has paid dividends for 4 years in our data.

Is Embecta a good stock to buy?

We do not give buy or sell advice. Embecta scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.